PTC Therapeutics Inc
NASDAQ:PTCT

Watchlist Manager
PTC Therapeutics Inc Logo
PTC Therapeutics Inc
NASDAQ:PTCT
Watchlist
Price: 45.28 USD -2.08%
Market Cap: 3.5B USD
Have any thoughts about
PTC Therapeutics Inc?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

244
Current
-12.6
Median
4.2
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
244
=
Enterprise Value
4.6B USD
/
EBITDA
18.8m USD
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
US
PTC Therapeutics Inc
NASDAQ:PTCT
Average EV/EBITDA: 48.7
244
470%
0.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 476 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.2
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16.1
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.8
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.8 N/A N/A
AU
CSL Ltd
ASX:CSL
19.7
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.3
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -109.5 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-59.5
2-Years Forward
EV/EBITDA
-142.3
3-Years Forward
EV/EBITDA
54.2

See Also

Discover More